Literature DB >> 30506912

Increased interleukin-23 receptor (IL-23R) expression is associated with disease severity in acute-on-chronic liver failure.

Arshi Khanam1, Nirupma Trehanpati1, Shiv Kumar Sarin1,2.   

Abstract

BACKGROUND: Th17 cells mediated immune response is important in chronic hepatitis B (CHB) infection and inflammation associated diseases; however, little is known about their immunopathogenic role in acute-on-chronic liver failure (ACLF). Interleukin-23 receptor (IL-23R) is essential for the generation of pathogenic Th17 cells; therefore, we aimed to evaluate IL-23R expression and its correlation with disease severity in ACLF.
METHODS: Forty-two patients with ACLF (HBV and alcohol-related), thirty-two with CHB and twenty healthy controls (HC) were studied. Circulating and intrahepatic profile of Th17 cells and IL-23R was investigated. Association of IL-23R with disease severity was determined.
RESULTS: Circulating Th17 cells were significantly increased in both ACLF groups (P = 0.03, P = 0.006) than CHB and HC. Percentage of Th17 cells was higher in liver than peripheral blood of ACLF patients (P = 0.04). Expression of IL-23R was immensely up-regulated on Th17 cells of ACLF patients. Importantly, IL-23R not only correlated with the increased percentage of Th17 cells but also had significant association with inflammation (P = 0.03) and clinical disease severity indices including Child-Turcotte-Pugh (P = 0.001) and Model for End-Stage Liver Disease (P = 0.002) scores. The ACLF non-survivors showed higher IL-23R expression (P = 0.01). Transcription factor retinoic acid receptor-related orphan nuclear receptor gamma-t (ROR-γt) was also high in circulation and in liver of ACLF patients and it positively correlated with ALT levels (P = 0.03). Surface receptors, including CCR6, IL-17R and pro-inflammatory cytokines IL-17A, IL-22, CXCL8 and GM-CSF were highly augmented in ACLF.
CONCLUSION: ACLF patients express high IL-23R on Th17 cells which induces inflammation and strongly correlates with liver disease severity.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IL-17A; IL-23R; alcoholic hepatitis; cirrhosis; hepatitis B; liver failure

Mesh:

Substances:

Year:  2019        PMID: 30506912     DOI: 10.1111/liv.14015

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  Association Between Serum IL-6, IL-10, IL-12, and IL-23 Levels and Severity of Liver Cirrhosis.

Authors:  Imelda Rey; Rustam Effendi-Ys
Journal:  Med Arch       Date:  2021-06

2.  Treg/Th17 Cell Balance in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure at Different Disease Stages.

Authors:  Nian-Hua Tan; Bin Chen; Jie Peng; Shan Du
Journal:  Biomed Res Int       Date:  2021-11-26       Impact factor: 3.411

Review 3.  Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management.

Authors:  Arshi Khanam; Shyam Kottilil
Journal:  Front Med (Lausanne)       Date:  2021-11-08

Review 4.  Fine-tuning of regulatory T cells is indispensable for the metabolic steatosis-related hepatocellular carcinoma: A review.

Authors:  Farooq Riaz; Ping Wei; Fan Pan
Journal:  Front Cell Dev Biol       Date:  2022-07-15

Review 5.  Serum Interleukins as Potential Prognostic Biomarkers in HBV-Related Acute-on-Chronic Liver Failure.

Authors:  Lili Zhang; Jianhua Hu; Chunyan Gou; Hua Jin; Chun Zhang; Yang Liu; Yitong Wang; Xiaojun Wang
Journal:  Mediators Inflamm       Date:  2022-09-08       Impact factor: 4.529

Review 6.  Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression.

Authors:  Arshi Khanam; Joel V Chua; Shyam Kottilil
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

Review 7.  Abnormal Innate Immunity in Acute-on-Chronic Liver Failure: Immunotargets for Therapeutics.

Authors:  Arshi Khanam; Shyam Kottilil
Journal:  Front Immunol       Date:  2020-10-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.